Neurotech Insider #3: BCI BS, Commercial Culture, Recycled Innovation, Join my Investor Rolodex, and More
Caveat Emptor: Not All BCI are Created Equal!
Aloha, dear readers. As we like to say around these parts, Happy Friday! 🥳
A note to new subscribers who signed up after last week’s Funding Snapshot: This (Neurotech Insider) is a monthly digest for paying or evangelizing members, with exclusive analysis and opportunities. My free market coverage (Neurotech Notables) ships biweekly; Edition #27 is in oven for Monday 3/17. Share your questions or ideas by replying to this email, or sending me a note.
1. A Revealing Revelation: A new BCI Subsidiary Is The Wrong Kind of Signal
Yesterday, Revelation Neuro, Inc. (“Revelation Neuro”) emerged as Helius Medical Technologies’ newly announced, “wholly-owned private subsidiary focused on the development of non-implantable AI powered BCI technology.”
Unlike the befuddled hypeclicking masses fawning over all things BCI, you, intelligent and esteemed reader of this newsletter that you are, understand that a press release is not the real story, but merely a cipher of corporate strategy. Look for the pattern and you’ll inevitably find certain, um, revelations.
